Search research articles
Contact Us
Filters
Showing results (101-110 of 108) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 108 results.
Vnitrni Lekarstvi
|
January 8, 2008
[Recommendations for early identification of damage to the skeleton by malignant processes, and for early diagnosis of multiple myeloma]
Z Adam, J Bednarík, J Neubauer, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|
September 17, 2025
Description of TEMPI syndrome in Waldenström's macroglobulinemia
Z Adam, L N Leová, M Patočková, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|
October 30, 2025
Precision medicine in hemato-oncology - treatment of refractory multiple myeloma with massive extramedullary involvement using BRAF/ MEK inhibitors
M Štork, J Kotašková, E Ondroušková, et al.
Leukemia
|
December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia
|
August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
P Moreau, D Joshua, W-J Chng, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|
September 13, 2011
Low molecular weight heparins for thromboprophylaxis during induction chemotherapy in patients with multiple myeloma
P Kessler, L Pour, E Gregora, et al.
Vnitrni Lekarstvi
|
April 24, 2002
[Quality of life and tolerance of maintenance therapy in patients with multiple myeloma]
Z Adam, L Pour, A Svobodník, et al.
Leukemia
|
July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R Hájek, T Masszi, M T Petrucci, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 108) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 108 results.
Vnitrni Lekarstvi
|
January 8, 2008
[Recommendations for early identification of damage to the skeleton by malignant processes, and for early diagnosis of multiple myeloma]
Z Adam, J Bednarík, J Neubauer, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|
September 17, 2025
Description of TEMPI syndrome in Waldenström's macroglobulinemia
Z Adam, L N Leová, M Patočková, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|
October 30, 2025
Precision medicine in hemato-oncology - treatment of refractory multiple myeloma with massive extramedullary involvement using BRAF/ MEK inhibitors
M Štork, J Kotašková, E Ondroušková, et al.
Leukemia
|
December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia
|
August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
P Moreau, D Joshua, W-J Chng, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|
September 13, 2011
Low molecular weight heparins for thromboprophylaxis during induction chemotherapy in patients with multiple myeloma
P Kessler, L Pour, E Gregora, et al.
Vnitrni Lekarstvi
|
April 24, 2002
[Quality of life and tolerance of maintenance therapy in patients with multiple myeloma]
Z Adam, L Pour, A Svobodník, et al.
Leukemia
|
July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R Hájek, T Masszi, M T Petrucci, et al.
Page
of 11